Status: Recruiting
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.
Participants needed: 120
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Brian RiniUpdated: Jul 2, 2026Locations: 2
Eligibility criteria
Signed informed consent and HIPAA authorization for release of personal health i... [+14]
Prior systemic therapy against renal cell carcinoma in the neo/adjuvant or metas... [+11]